To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However, accounting considerations...

Supplements the (A) case. Describes the CEO's decision.

Supplements the (A) case. Describes the implementation of the CEO's decision.

Supplements the (A) case. Describes the aftermarket performance of the units.